Our Mission

To demonstrate the clinical efficacy of FE 203799, a novel proprietary Glucagon-Like Peptide-2 (GLP-2) analogue exerting unique pharmacological effects in a first-in-class, meaningful indication for patients with hematological malignancies receiving myelotoxic therapies.